NeuVax
NeuVax
NeuVax (pronounced: new-vax) is a cancer vaccine currently under development for the prevention of cancer recurrence following initial treatment. It is specifically designed for patients with low-to-intermediate HER2 expression levels, which is a protein that promotes the growth of cancer cells.
Etymology
The term "NeuVax" is a combination of "neu", a reference to the neu oncogene, and "vax", a common abbreviation for vaccine. The neu oncogene is often associated with the development of various types of cancer, including breast cancer and ovarian cancer.
Mechanism of Action
NeuVax works by stimulating the body's immune system to target and destroy cells expressing the HER2 protein. It does this by presenting a specific peptide (E75) to the immune system, which then recognizes this peptide as a threat and mounts an immune response against cells expressing it.
Clinical Trials
NeuVax has undergone several clinical trials to assess its safety and efficacy. These trials have shown promising results, with NeuVax demonstrating a significant reduction in cancer recurrence in patients with low-to-intermediate HER2 expression.
Related Terms
External links
- Medical encyclopedia article on NeuVax
- Wikipedia's article - NeuVax
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski